数据加载中.....
|
jsp.display-item.identifier=請使用永久網址來引用或連結此文件:
https://ir.csmu.edu.tw:8080/ir/handle/310902500/24109
|
| 题名: | Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study |
| 作者: | Chiu, TJ;Su, YY;Yang, SH;Li, CP;Bai, LY;Chiang, NJ;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Chen, YY;Chen, JS;Chou, WC |
| 关键词: | dose reduction;liposomal irinotecan;outcome;pancreatic cancer;toxicity |
| 日期: | 2021 |
| 上传时间: | 2022-08-05T09:47:57Z (UTC)
|
| 出版者: | SAGE PUBLICATIONS LTD |
| ISSN: | 1758-8340 |
| 摘要: | Background: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is currently the standard second-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC) after previous failed gemcitabine-based therapy. This population-based study aimed to evaluate the efficacy and safety of nal-IRI + 5-FU/LV and the association of pre-emptive nal-IRI dosing with treatment outcomes in patients with PDAC. Methods: We retrospectively enrolled a total of 667 consecutive patients with PDAC who received nal-IRI plus 5-FU/LV treatment between August 2018 and November 2020 at 9 medical centers in Taiwan. Patients were allocated into groups according to pre-emptive nal-IRI dosing (> 75%, 50-74%, <50%) for comparison of treatment efficacy and safety. Results: The median overall survival (OS) and time to treatment failure (TTF) were 5.9 months [95% confidence interval (CI), 5.3-6.5] and 2.8 months (95% CI, 2.6-3.0), respectively. The median OS was 6.5 months (95% CI, 5.7-6.7), 5.0 months (95% CI, 3.4-6.5), and 4.1 months (95% CI, 2.7-5.6), respectively, among the > 75%, 50-74%, and <50% pre-emptive nal-IRI dosing groups, whereas the median TTF of the three groups was 3.0 months (95% CI, 2.6-3.4), 2.6 months (95% CI, 2.3-2.9), and 1.9 months (95% CI, 1.6-2.2), respectively. Pre-emptive nal-IRI dosing <50% was an independent negative prognostic factor for OS and TTF in multivariate analyses. The most common severe adverse events were neutropenia (22.9%), anemia (21.1%), and hypokalemia (15.4%). Patients in the Conclusion: Our results support the use of nal-IRI + 5-FU/LV as standard clinical practice for treating patients with PDAC based on this large population-based study. Our findings encourage physicians to provide adequate doses of nal-IRI in order to achieve better outcomes without compromising safety profiles. |
| URI: | http://dx.doi.org/10.1177/17588359211058255
https://www.webofscience.com/wos/woscc/full-record/WOS:000721359600001
https://ir.csmu.edu.tw:8080/handle/310902500/24109 |
| 關聯: | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY ,2021,v13 |
| 显示于类别: | [中山醫學大學研究成果] 期刊論文
|
文件中的档案:
| 档案 |
描述 |
大小 | 格式 | 浏览次数 |
|---|
| index.html | | 0Kb | HTML | 203 | 检视/开启 |
|
在CSMUIR中所有的数据项都受到原著作权保护.
|
